Revolution Medicines: Short Interest Jumps 30% as Rasonque Launch Sets the Stakes

RVMD is a clinical-stage oncology company whose first commercial product, the RAS inhibitor Rasonque, received FDA approval for metastatic pancreatic cancer earlier this year. The company reports third-quarter results on November 4, with short sellers meaningfully more active than they were a month ago.

Short interest has climbed 30% over the past month to 6.6% of the free float, with the sharpest move concentrated in the week ending October 26, when positions jumped 9.3%. That weekly surge brought short shares to roughly 12.8 million, the highest level in the 30-day window. The build is notable against a stock that has gained 150% year-to-date, suggesting a portion of the new short positioning reflects skepticism specifically about the commercial launch rather than a fundamental view on the pipeline. The borrow market is loose: availability runs at more than 4,000% of short interest, and the cost to borrow remains below 0.5%, so the shorts are entering with very little friction.

Options positioning has shifted more bullish into the print. The put/call ratio dropped to 0.79 on October 30, more than one standard deviation below its 20-day average of 0.90, with calls clearly dominating recent flow. That stands in contrast to the short interest build. Retail attention has also spiked, with Wikipedia page views running at a z-score of 4.7 against the prior 90 days as of mid-October, a sign the Rasonque launch story is drawing a wider audience beyond specialist biotech investors.

The analyst community is firmly positive but watching the launch closely. Coverage has expanded in recent weeks, with Goldman Sachs reinstating with a Buy and a $267 target in late September, William Blair initiating at Outperform in mid-October, and Brookline Capital opening coverage with a $318 target. RBC Capital raised its target twice in October to $260, while Needham holds at $275. The mean consensus target of $258 implies roughly 35% upside from the current $191 level. The bull case rests on modeled peak sales of $21.2 billion for Rasonque across pancreatic and other RAS-driven cancers, with additional pipeline assets in NSCLC and CRC adding depth. The bear case is more immediate: third-quarter Rasonque revenue is being modeled by some at $19.5 million against a Street consensus closer to $26 million, with uncertainty around prescription capture rates, net pricing realization, inventory stocking and conversion from the expanded access program all making the launch trajectory hard to underwrite in the first full commercial quarter.

Insider activity over the past 90 days shows net selling of approximately $34.8 million in shares, though every transaction in the window was executed under pre-arranged 10b5-1 trading plans, which limits the informational weight. The Chief Development Officer sold shares in late September, and other insiders followed in October, all under plan. On the institutional side, Vanguard Capital Management filed a fresh Schedule 13G on October 30 disclosing a 5.13% stake, the most recent addition to a register that already includes BlackRock at 5.7%, Farallon at 6.4% and Baker Bros at 5.3%. No 13D activist filing is on record. ORTEX puts the probability of RVMD joining the Nasdaq-100 at the December 2026 Annual Review at 27%, which would require a close above $204.35 to cross the entry threshold. The stock closed at $191.31.

The November 4 print is less a test of whether Rasonque works clinically and more a test of whether the first full commercial quarter's numbers land close enough to the $26 million consensus to justify a stock that has already priced in a transformative launch.